Cargando…
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
BACKGROUND: High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy is also refractory to a subsequent combine...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626404/ https://www.ncbi.nlm.nih.gov/pubmed/31300044 http://dx.doi.org/10.1186/s40425-019-0655-4 |